我们开发了水溶性差的分子氯硝柳胺的无定形固体分散体(ASD),其生物利用度提高了两倍以上。值得注意的是,由于纳米颗粒的产生,这种氯硝柳胺ASD制剂相对于晶体材料增加了约60倍的表观药物溶解度。氯硝柳胺是一种弱酸性药物,生物制药分类系统(BCS)II类,和不良的玻璃形成剂,体内生物利用度低。热熔挤出是一种高通量制造方法,通常用于开发ASD,以提高水溶性差的化合物的表观溶解度和生物利用度。我们利用聚合物聚(1-乙烯基吡咯烷酮-共-乙酸乙烯酯)(PVP-VA)通过挤出制造氯硝柳胺ASD。根据样品的微观和宏观行为及其分子间相互作用进行分析,使用差示扫描量热法(DSC),X射线衍射(XRD)核磁共振(NMR),傅里叶变换红外(FTIR),和动态光散射(DLS)。氯硝柳胺ASD在FaSSIF介质中产生平均粒度为约100nm的纳米颗粒。在并排扩散测试中,这些纳米粒子使氯硝柳胺的扩散增加了4倍.我们成功地制造了不良玻璃前氯硝柳胺的无定形挤出物,该挤出物显示出显着的体外溶解和扩散性能。这些体外测试被转化为大鼠模型,该模型也显示口服生物利用度增加。
We developed an amorphous solid dispersion (ASD) of the poorly water-soluble molecule
niclosamide that achieved a more than two-fold increase in bioavailability. Notably, this
niclosamide ASD formulation increased the apparent drug solubility about 60-fold relative to the crystalline material due to the generation of nanoparticles.
Niclosamide is a weakly acidic drug, Biopharmaceutics Classification System (BCS) class II, and a poor glass former with low bioavailability in vivo. Hot-melt extrusion is a high-throughput manufacturing method commonly used in the development of ASDs for increasing the apparent solubility and bioavailability of poorly water-soluble compounds. We utilized the polymer poly(1-vinylpyrrolidone-co-vinyl acetate) (PVP-VA) to manufacture
niclosamide ASDs by extrusion. Samples were analyzed based on their microscopic and macroscopic behavior and their intermolecular interactions, using differential scanning calorimetry (DSC), X-ray diffraction (XRD), nuclear magnetic resonance (NMR), Fourier-transform infrared (FTIR), and dynamic light scattering (DLS). The
niclosamide ASD generated nanoparticles with a mean particle size of about 100 nm in FaSSIF media. In a side-by-side diffusion test, these nanoparticles produced a four-fold increase in niclosamide diffusion. We successfully manufactured amorphous extrudates of the poor glass former niclosamide that showed remarkable in vitro dissolution and diffusion performance. These in vitro tests were translated to a rat model that also showed an increase in oral bioavailability.